DXS International plc Collaboration And Licensing Agreement
18 August 2022 - 4:00PM
UK Regulatory
TIDMDXSP
DXS INTERNATIONAL PLC
COLLABORATION AND LICENSING AGREEMENT
The Board of DXS International plc ("the Company"), the AQSE
Growth Market quoted healthcare information and digital clinical
decision support systems provider, is pleased to announce that it
has entered into a Licence and Services Agreement with a world
leading AI company to help improve clinical pathway implementation
in Primary Care.
DXS has partnered with Deontics to help solve some of the most
critical objectives in healthcare, saving the clinician time,
helping with decision fatigue, and integrating pathways into
clinicians' workflows.
DXS has more than 20 years of experience in primary care
clinical decision support, is integrated into the three major
clinical systems, and is proven to significantly reduce referral
bounce while providing a wealth of up-to-date clinical resources to
the clinician.
Deontics is a world-leading clinical AI company, which spun out
from Oxford University, Cancer Research UK and UCL. Deontics has
one of the most sophisticated AI analytic and clinical decision
engines on the market, with over 300 peer-reviewed published
scientific and clinical evaluations. Deontics is a pioneer in
cognitive computing within healthcare and has developed a
prize-winning clinical logic model.
Clinical decision support systems are traditionally built with
"if-then" rule engines and decision trees. These are not able to
deal with uncertainty and complex non-linear disease management.
They are also not equipped to capture domain expertise in knowledge
frameworks. This is because they are not dynamic and or flexible to
allow for situationally-adaptive execution at the point of
care.
Deontics has solved these challenges; it is unique in its
offering and the only solution on the market that blends clinical
process (workflow) and complex reasoning and knowledge
representation and is capable of running the pathway both
prospectively on individual patient data and retrospectively on
batch data.
Integrating the Deontics engine into the DXS platform will
greatly enhance the capabilities of DXS.
This integration will enable DXS to offer additional features
and functions to its customers. These include advanced 3rd
generation clinical decision support and advanced analytics that
will dynamically guide and inform clinical teams for management
decisions.
Primary Care, like all healthcare sectors, are struggling to
keep on top of patient demand, and digital solutions can help
streamline workflows and accelerate better patient outcomes.
DXS currently provides around 2500 practices serving 16 Million
patients with its decision support solution that is proven to
virtually eliminate unwarranted or inappropriate referrals through
its unique SMART Referral solutions. SMART Referrals reduce patient
waiting times, hospital backlog and repeat appointments in primary
care.
By DXS integrating the Deontics Advanced AI engine, DXS can
offer improvements to the adoption of pathways, making
consultations more efficient, improving data quality, reducing
decision fatigue for busy GPs, and ultimately improving patient
outcomes.
Steven Bauer, DXS COO said "We are excited to be working with
Deontics to be able to bring much-needed benefits to primary care
that will improve the working lives of primary care staff, GPs and
nurses as well as easing down-stream pressures in secondary care,
mental health and social care. We are a company passionate about
improving the lives of care providers and patients alike, and this
collaboration with Deontics enables us to do much more of what we
are passionate about."
Michelle Lea, Deontics CEO said " We are delighted to be working
with DXS this is truly a pioneering partnership that will advance
the offering across primary and secondary care using the Deontics
advanced AI engine.
We hope this collaboration will be a great start of the two
parties' long-term partnership, and we look forward to bringing
more life-changing options to patients."
The Directors of DXS International plc accept responsibility for
this announcement.
Contacts :
David Immelman 01252 719800
DXS International plc
www.dxs-systems.com
AQSE Corporate Broker
Hybridan LLP 020 3764 2341
Claire Louise Noyce
Corporate Advisor
City & Merchant 020 7101 7676
David Papworth
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other
trusted NHS sources, to doctors, nurses and pharmacists in their
workflow and during the patient consultation. This effective
clinical decision support ultimately translates to improved
healthcare outcomes delivered more cost effectively and which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
(END) Dow Jones Newswires
August 18, 2022 02:00 ET (06:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
DXS (AQSE:DXSP)
Historical Stock Chart
From Aug 2024 to Sep 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Sep 2023 to Sep 2024